SynthesisMultiple sclerosis and related disorders2023
Reliability of paramagnetic rim lesion classification on quantitative susceptibility mapping (QSM) in people with multiple sclerosis: Single-site experience and systematic review.
Synthesis in Multiple sclerosis and related disorders, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 23 citations in OpenAlex.
- TAnnals of clinical and translational neurology · 2026Article
- Filtered-phase imaging versus susceptibility-weighted imaging for paramagnetic rim lesion detection in multiple sclerosis: A head-to-head comparison.Multiple sclerosis (Houndmills, Basingstoke, England) · 2026Article
- Insights From Quantitative Susceptibility Mapping: An Umbrella Review of Multiple Sclerosis.Health science reports · 2026Review
- Hidden Pitfall in Multiple Sclerosis Imaging: How Standard Susceptibility-Weighted Imaging (SWI) May Miss Paramagnetic Rim Lesions.Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine · 2026Article
- Smoldering neuroinflammation in progressive multiple sclerosis: mechanisms, imaging biomarkers, and therapeutic opportunities.Frontiers in immunology · 2026Review
- Quantitative susceptibility mapping of paramagnetic rim lesions in early multiple sclerosis: A cross-sectional study of brain age and disability.Neuroimage. Reports · 2025Article
- Paramagnetic rim lesions are associated with choroid plexus inflammation and expansion over 5 years in people with multiple sclerosis.Journal of neurology · 2025Article
- Diffusion- and Tractography-Based Characterization of Tissue Damage Within and Surrounding Paramagnetic Rim Lesions in Multiple Sclerosis.AJNR. American journal of neuroradiology · 2025Article
- Determinants of long-term paramagnetic rim lesion evolution in people with multiple sclerosis.Annals of clinical and translational neurology · 2025Article
- Association between paramagnetic rim lesions and pulvinar iron depletion in persons with multiple sclerosis.Multiple sclerosis and related disorders · 2025Article
- Paramagnetic rim lesions are highly specific for multiple sclerosis in real-world data.Brain communications · 2025Article
- Imaging Outcomes for Phase 2 Trials Targeting Compartmentalized Inflammation.Multiple sclerosis (Houndmills, Basingstoke, England) · 2024Review
- Associations Between Paramagnetic Rim Lesion Evolution and Clinical and Radiologic Disease Progression in Persons With Multiple Sclerosis.Neurology · 2024Article
- Central Vein Sign and Paramagnetic Rim Lesions: Susceptibility Changes in Brain Tissues and Their Implications for the Study of Multiple Sclerosis Pathology.Diagnostics (Basel, Switzerland) · 2024Review
- Article
- Paramagnetic rim lesions predict greater long-term relapse rates and clinical progression over 10 years.Multiple sclerosis (Houndmills, Basingstoke, England) · 2024Article
- Chronic active lesions in multiple sclerosis: classification, terminology, and clinical significance.Therapeutic advances in neurological disorders · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundRecent developments in iron-sensitive MRI techniques have enabled visualization of chronic active lesions as paramagnetic rim lesions (PRLs) in vivo. Although PRLs have potential as a diagnostic and prognostic tool for multiple sclerosis (MS), limited studies have reported the reliability of PRL assessment. Further evaluation of PRL reliability, through original investigations and review of PRL literature, are warranted.
methodsA single-center cohort study was conducted to evaluate the inter-rater reliability of PRL identification on quantitative susceptibiltiy mapping (QSM) in 10 people with MS, 5 people with clinically isolated syndrome, and 5 healthy controls. An additional systematic literature search was then conducted of published PRL reliability data, and these results were synthesized.
resultsIn the single-center study, both inter-rater and intra-rater reliability of per-subject PRL number were at an "Excellent" (intraclass correlation coefficient (ICC) of 0.901 for both) level with only 2-years lesion classification experience. Across the reported literature values, reliability of per-lesion rim presence was on average "Near perfect" (for intra-rater; Cohen's κ = 0.833) and "Substantial" (for inter-rater; Cohens κ = 0.687), whereas inter-rater reliability of per-subject PRL number was "Good" (ICC = 0.874). Only 4/22 studies reported complete information on rater experience, rater level of training, detailed PRL classification criteria, and reliability cohort size and disease subtypes.
conclusionPRLs can be reliably detected both at per-lesion and per-subject level. We recommend that future PRL studies report detailed reliability results, including rater experience level, and use a standardized set of reliability metrics (Cohen's κ or ICC) for improved comparability between studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.